Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

  • ID: 3783283
  • Report
  • 158 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abeome Corporation
  • BeiGene, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • IO Biotech ApS
  • Merck KGaA
  • Theravectys SA
  • MORE
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016

Summary

‘Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016’, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted pipeline therapeutics.

The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
- The report reviews Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics and enlists all their major and minor projects
- The report assesses Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeome Corporation
  • BeiGene, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • IO Biotech ApS
  • Merck KGaA
  • Theravectys SA
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Overview

Therapeutics Development

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Stage of Development

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Therapy Area

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Indication

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Companies

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Products under Development by Universities/Institutes

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Companies Involved in Therapeutics Development

Abeome Corporation

Alnylam Pharmaceuticals, Inc.

AlphaMab Co., Ltd

AstraZeneca Plc

Aurigene Discovery Technologies Limited

BeiGene, Ltd.

Bristol-Myers Squibb Company

CytomX Therapeutics, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Genosco

ImmunoCellular Therapeutics, Ltd.

Immunocore Limited

IO Biotech ApS

Kadmon Corporation, LLC

MedImmune, LLC

Merck KGaA

Novartis AG

PsiOxus Therapeutics Limited

Regeneron Pharmaceuticals, Inc.

Shanghai Henlius Biotech Co., Ltd.

Sorrento Therapeutics, Inc.

Sutro Biopharma, Inc.

Theravectys SA

Tikcro Technologies, Ltd.

ViiV Healthcare Limited

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Drug Profiles

ALN-PDL - Drug Profile

Antibody to Inhibit PD-L1 for Oncology - Drug Profile

atezolizumab - Drug Profile

AUPM-327 - Drug Profile

avelumab - Drug Profile

Biologic to Inhibit PD-L1 for Immunology - Drug Profile

BMS-936559 - Drug Profile

CA-170 - Drug Profile

CBA-0710 - Drug Profile

CX-072 - Drug Profile

dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile

durvalumab - Drug Profile

durvalumab + gefitinib - Drug Profile

durvalumab + IMCgp-100 + tremelimumab - Drug Profile

durvalumab + MEDI-0680 - Drug Profile

durvalumab + MEDI-6383 - Drug Profile

durvalumab + MEDI-9447 - Drug Profile

durvalumab + monalizumab - Drug Profile

durvalumab + tremelimumab - Drug Profile

GNS-1480 - Drug Profile

HLX-10 - Drug Profile

HLX-20 - Drug Profile

IO-103 - Drug Profile

KD-033 - Drug Profile

KN-035 - Drug Profile

LY-3300054 - Drug Profile

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile

Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile

Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile

Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile

Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile

Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile

Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology - Drug Profile

MSB-002 - Drug Profile

Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile

Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile

STIA-1011 - Drug Profile

STIA-1012 - Drug Profile

STIA-1014 - Drug Profile

STIA-1015 - Drug Profile

Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile

Synthetic Peptide 2 to Inhibit PDL1 for Oncology - Drug Profile

Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile

Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile

Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Dormant Projects

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Discontinued Products

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Abeome Corporation, H1 2016

Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Pipeline by AlphaMab Co., Ltd, H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by Aurigene Discovery Technologies Limited, H1 2016

Pipeline by BeiGene, Ltd., H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by CytomX Therapeutics, Inc., H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Genosco, H1 2016

Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016

Pipeline by Immunocore Limited, H1 2016

Pipeline by IO Biotech ApS, H1 2016

Pipeline by Kadmon Corporation, LLC, H1 2016

Pipeline by MedImmune, LLC, H1 2016

Pipeline by Merck KGaA, H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by PsiOxus Therapeutics Limited, H1 2016

Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016

Pipeline by Sorrento Therapeutics, Inc., H1 2016

Pipeline by Sutro Biopharma, Inc., H1 2016

Pipeline by Theravectys SA, H1 2016

Pipeline by Tikcro Technologies, Ltd., H1 2016

Pipeline by ViiV Healthcare Limited, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abeome Corporation
  • BeiGene, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • IO Biotech ApS
  • Merck KGaA
  • Theravectys SA
  • MORE
Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) Programmed death-ligand 1 (PD-L1) or CD274 or B7 homolog 1 (B7-H1) is a protein encoded by the CD274 gene. It is involved in the costimulatory signal essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.

Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) pipeline Target constitutes close to 48 molecules. Out of which approximately 46 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 2, 7, 1, 26 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Our latest report Programmed Cell Death 1 Ligand 1 – Pipeline Review, H1 2016, outlays comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Abeome Corporation
Alnylam Pharmaceuticals, Inc.
AlphaMab Co., Ltd
AstraZeneca Plc
Aurigene Discovery Technologies Limited
BeiGene, Ltd.
Bristol-Myers Squibb Company
CytomX Therapeutics, Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genosco
ImmunoCellular Therapeutics, Ltd.
Immunocore Limited
IO Biotech ApS
Kadmon Corporation, LLC
MedImmune, LLC
Merck KGaA
Novartis AG
PsiOxus Therapeutics Limited
Regeneron Pharmaceuticals, Inc.
Shanghai Henlius Biotech Co., Ltd.
Sorrento Therapeutics, Inc.
Sutro Biopharma, Inc.
Theravectys SA
Tikcro Technologies, Ltd.
ViiV Healthcare Limited
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll